New study reveals increased risk of allergic diseases after COVID-19 infection

FHS
April 3, 2024
8:57 am

The association of COVID-19 with long term allergic conditions.

Nura Bio raises $68M for clinical tests of SARM1 inhibitor to potentially slow or prevent nerve degeneration

A promising new approach that could slow, stop or prevent nerves from dying may get its first test in patients next year.Nura Bio, a …

September 18, 2024

EASD 2024: Novel insights into maternal protection in T1D – Pharmaceutical Technology

At the European Association for the Study of Diabetes (EASD) 2024 conference, results were presented for a meta-analysis, shedding new light on the genetic transmission

September 10, 2024

UNAIDS boss calls on Gilead to provide ‘miracle’ drug to developing countries

UNAIDS executive director Winnie Byanyima speaking at a conference. Gilead recently presented data from the PURPOSE 1 trial of Sunlenca showing 100% prevention in cisgender

July 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.